Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their vaccination history. Seropositivity rates for antibodies against pertussis toxin had begun to decline by 5 years after a booster dose of Tdap in adolescents/adults, with a subsequent booster dose 10 years later generally as immunogenic and as well tolerated as the initial booster. Tdap was safe and well tolerated in all age groups.
- Di Pasquale A, Wolter J, Schuerman L. Management of pertussis in adolescents and adults: the role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. J Prev Med Hyg. 2005;46(1):33–41.
- Halperin SA, Scheifele D, De Serres G, et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012;30(5):974–82. CrossRef
- World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85(40):385–400.
- McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its use as a single-dose booster immunization. Drugs. 2012;72(13):1765–91. CrossRef
- Center for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with infants aged <12 months: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(11):1424–6.
- Health Protection Agency: HPA guidelines for the public health management of pertussis (online). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287142671506. Accessed 2 Nov 2012.
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed): US prescribing information. Research Triangle Park (SC): GlaxoSmithKline;2012.
- Boostrix suspension for injection (diphtheria, tetanus and pertussis [acellular, component] vaccine [adsorbed, reduced antigen(s) content]): summary of product characteristics. London: European Medicines Agency;2012.
- Zhu F, Zhang S, Hou Q, et al. Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™). Hum Vaccin. 2010;6(3):263–9. CrossRef
- Huang LM, Chang LY, Tang H, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents. J Adolesc Health. 2005;37(6):517.e1–5. CrossRef
- Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine. 2003;21(27–30):4194–200. CrossRef
- Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in pre-school-aged children [abstract no. 281.00 plus poster]. In: 21st Annual Meeting of the European Society for Paediatric Infectious Diseases, 9–11 Apr 2003, Taormina, Italy.
- Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084–93. CrossRef
- Theeten H, Van Damme P, Hoppenbrouwers K, et al. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine. 2005;23(12):1515–21. CrossRef
- Abarca K, Valdivieso F, Potin M, et al. Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine (dTpa) in 10 to 11 years old children and in adults [in Spanish]. Rev Med Chil. 2002;130(5):502–10.
- Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine. 2006;24(12):2043–8. CrossRef
- Southern J, Andrews N, Burrage M, et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine. 2005;23(29):3829–35. CrossRef
- Tran Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999; 104(6):e70.
- Booy R, Van Der Meeren O, Ng SP, et al. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine. 2010;29(1):45–50. CrossRef
- Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis. 2010;51(6):656–62. CrossRef
- Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age. Vaccine. 2009;27(5):765–72. CrossRef
- Chan SH, Tan PTN, Han HH, et al. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults. Singap Med J. 2006;47(4):286–90.
- Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine. 2000;19(6):628–36. CrossRef
- Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18(20):2075–82. CrossRef
- Weston WM, Friedland LR, Wu X, et al. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized trials. Vaccine. 2012;30(9):1721–8. CrossRef
- Schmitt HJ, von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275(1):37–41. CrossRef
- Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr. 1996;129(5):695–701. CrossRef
- Weston W, Messier M, Friedland LR, et al. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine. 2011;29(47):8483–6. CrossRef
- McIntyre PB, Turnbull FM, Egan AM, et al. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine. 2004;23(3):380–5. CrossRef
- Edelman K, He Q, Makinen J, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis. 2007;44(10):1271–7. CrossRef
- Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39(2):179–85. CrossRef
- Evaluation of GSK Biologicals’ Boostrix™ in healthy adults, 10 years after previous booster vaccination (result summary of study no. 113055). Brentford, UK: GlaxoSmithKline; 2011.
- McIntyre PB, Burgess MA, Egan A. Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine. 2009;27(7):1062–6. CrossRef
- Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Ped Infect Dis J. 2009;28(2):152–3. CrossRef
- Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555–63. CrossRef
- Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51(3):315–21. CrossRef
- Zepp F, Knuf M, Habermehl P, et al. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr. 2006;149(5):603–10. CrossRef
- Bose A, Dubey AP, Gandhi D, et al. Safety and reactogenicity of a low-dose diphtheria-tetanus-acellular pertussis vaccine (Boostrix™) in pre-school Indian children. Indian Pediatr. 2007;44(6):421–4.
- Vergara R, Tregnaghi M, Ussher J, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 2005;164(6):377–82. CrossRef
- Weston WM, Friedland LR, Wu X. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29(5):1017–22. CrossRef
- Weston WM, Chandrashekar V, Friedland LR, et al. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin. 2009;5(12):858–66.
- Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011;30(12):e225–34. CrossRef
- Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States Health Maintenance Organization. Pediatr Infect Dis J. 2010;29(7):613–7. CrossRef
- Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009;27(32):4257–62. CrossRef
- Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)
Volume 27, Issue 1 , pp 75-81
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors